| 标题 |
Efficacy of disitamab vedotin (RC48) plus tislelizumab and S-1 as first-line therapy for HER2-overexpressing advanced stomach or gastroesophageal junction adenocarcinoma: A multicenter, single-arm, phase II trial (RCTS) |
| 网址 | |
| DOI | |
| 其它 |
期刊:Journal of Clinical Oncology 作者:Song Li; Zimin Liu; Yanguo Liu; Kainan Li; Lei Cong; et al 出版日期:2024-06-17 |
| 求助人 | |
| 下载 | 求助已完成,仅限求助人下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)